(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of -48.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.73%.
Xilio Therapeutics's revenue in 2026 is $53,484,000.On average, 2 Wall Street analysts forecast XLO's revenue for 2026 to be $217,595,854, with the lowest XLO revenue forecast at $211,134,388, and the highest XLO revenue forecast at $226,217,125. On average, 2 Wall Street analysts forecast XLO's revenue for 2027 to be $172,521,145, with the lowest XLO revenue forecast at $167,393,852, and the highest XLO revenue forecast at $179,353,548.
In 2028, XLO is forecast to generate $44,895,224 in revenue, with the lowest revenue forecast at $43,561,051 and the highest revenue forecast at $46,678,110.